Cargando…
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Aggregation of biotherapeutics has the potential to induce an immunogenic response. Here, we show that aggregated therapeutic antibodies, previously generated and determined to contain a variety of attributes (Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., and Narhi, L. O. (2011) J. Biol. C...
Autores principales: | Joubert, Marisa K., Hokom, Martha, Eakin, Catherine, Zhou, Lei, Deshpande, Meghana, Baker, Matthew P., Goletz, Theresa J., Kerwin, Bruce A., Chirmule, Naren, Narhi, Linda O., Jawa, Vibha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408134/ https://www.ncbi.nlm.nih.gov/pubmed/22584577 http://dx.doi.org/10.1074/jbc.M111.330902 |
Ejemplares similares
-
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
por: Joubert, Marisa K., et al.
Publicado: (2016) -
Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects
por: Jawa, Vibha, et al.
Publicado: (2010) -
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023) -
An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines
por: Kale, Akanksha, et al.
Publicado: (2023) -
Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
por: Swanson, Michael D., et al.
Publicado: (2022)